Ken Griffin Igm Biosciences, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$6.28 - $17.68 $8,164 - $22,984	1,300 Added 33.33%	5,200 $86,000
Q2 2024 Aug 14, 2024	SELL	$6.51 - $11.47 $7,812 - $13,764	-1,200 Reduced 23.53%	3,900 $26,000
Q1 2024 May 15, 2024	BUY	$8.68 - $17.36 $12,152 - $24,304	1,400 Added 37.84%	5,100 $49,000
Q4 2023 Feb 14, 2024	BUY	$3.94 - $8.79 $10,244 - $22,853	2,600 Added 236.36%	3,700 $30,000
Q3 2023 Nov 14, 2023	SELL	$6.66 - $10.64 $5,328 - $8,512	-800 Reduced 42.11%	1,100 $9,000
Q2 2023 Aug 14, 2023	SELL	$8.86 - $14.0 $36,326 - $57,400	-4,100 Reduced 68.33%	1,900 $17,000
Q1 2023 May 15, 2023	SELL	$13.74 - $25.76 $48,090 - $90,160	-3,500 Reduced 36.84%	6,000 $82,000
Q4 2022 Feb 14, 2023	SELL	$15.45 - $26.02 $295,095 - $496,982	-19,100 Reduced 66.78%	9,500 $161,000
Q3 2022 Nov 14, 2022	BUY	$15.42 - $27.01 $225,132 - $394,346	14,600 Added 104.29%	28,600 $650,000

20.7M

68K

52.2K

Ticker IGMS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,969,000
Market Cap $189M
Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.